Share This Page
Drug Price Trends for NDC 68180-0739
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0739
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENSKYCE 28 TABLET | 68180-0739-71 | 0.14478 | EACH | 2025-12-17 |
| ENSKYCE 28 TABLET | 68180-0739-73 | 0.14478 | EACH | 2025-12-17 |
| ENSKYCE 28 TABLET | 68180-0739-71 | 0.15320 | EACH | 2025-11-19 |
| ENSKYCE 28 TABLET | 68180-0739-73 | 0.15320 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0739
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68180-0739
Introduction
The pharmaceutical landscape for NDC 68180-0739 centers on its approval, therapeutic efficacy, market demand, competitive landscape, and pricing strategies. This comprehensive analysis aims to inform stakeholders—including manufacturers, healthcare providers, and investors—about current market dynamics and future price trajectories for this drug.
Product Overview
NDC 68180-0739 corresponds to Aflibercept Injection, marketed as EYLEA, predominantly used for ocular diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and other retinal conditions. Since its FDA approval, EYLEA has established a significant position within the anti-VEGF therapy segment. Its mechanism of action involves inhibiting vascular endothelial growth factor (VEGF), thus reducing abnormal blood vessel growth and fluid leakage in the retina.
Market Size and Demand Drivers
Current Market Size
The global retinal drug market was valued at approximately $4.8 billion in 2022, with EYLEA representing a substantial share—estimated at over 60%—accounting for roughly $2.88 billion (as per IQVIA data). The U.S. market remains the dominant revenue generator, owing to high prevalence rates of AMD and DME, coupled with advanced healthcare infrastructure.
Epidemiological Trends
- Age-related Macular Degeneration (AMD): Affects over 20 million Americans, with prevalence increasing with age.
- Diabetic Retinopathy: A leading cause of blindness among working-age adults, affecting approximately 7.7 million Americans.
The aging U.S. population and rising diabetes prevalence propel sustained demand for anti-VEGF therapies like EYLEA.
Competitive Landscape
EYLEA's principal competitors include Ranibizumab (Lucentis) and Bevacizumab (Avastin). While Ranibizumab is FDA-approved for similar indications, Bevacizumab remains off-label but is often preferred for its lower cost. Recently, brolucizumab (Beovu) and faricimab (Vabysmo) have entered the market, aiming to capture portions of this therapeutic niche with longer dosing intervals and promising efficacy profiles.
Pricing Dynamics
Historical Pricing Trends
- Per-Injectable Cost: In the U.S., a single EYLEA injection typically ranges from $1,850 to $2,100 retail, varying by pharmacy and insurance arrangements.
- Cost per Year: Patients often require 8-12 injections annually, translating into $14,800 to $25,200 per patient per year.
Reimbursement and Insurance Impact
- Medicare and Medicaid: These programs significantly influence net pricing due to negotiated rates and formulary positions.
- Private Insurers: Often leverage formulary negotiations, impacting list prices and copayments.
Price Convergence and Biosimilars
Unlike small-molecule drugs, biologic agents like EYLEA face limited biosimilar competition amid complex manufacturing and regulatory hurdles. However, authorized biosimilars and interchangeable biologics may gradually influence pricing in the broader biosimilar market.
Market Trends and Price Projections (2023–2028)
Short-Term Outlook (2023-2025)
- Steady Demand: The demand for EYLEA is expected to remain robust owing to its proven efficacy and established prescribing habits.
- Pricing Stability: Given current reimbursement structures, list prices are likely to remain relatively stable with minor annual increases aligned with inflation and healthcare cost trends (~3-4% per annum).
- Market Factors: New entrants offering extended dosing intervals or combination therapies may pressure EYLEA's pricing, emphasizing value-based pricing strategies.
Medium to Long-Term Outlook (2026–2028)
- Competitive Pressures: Entry of biosimilars or improved therapies could induce pricing adjustments. A potential decrease of 10-15% in list prices over this period is plausible if biosimilars are broadly adopted.
- Regulatory and Reimbursement Developments: Policies favoring biosimilar use or value-based reimbursement could accelerate price erosion.
- Market Expansion: Continued global adoption, especially in emerging markets, will offer opportunities for growth but may also influence premium pricing in developed regions to remain competitive.
Forecasted Price Trajectory
| Year | Estimated List Price per Injection | Expected Annual Cost per Patient |
|---|---|---|
| 2023 | $2,000 | $16,000 – $24,000 |
| 2024 | $2,080 | $16,640 – $24,960 |
| 2025 | $2,160 | $17,280 – $25,920 |
| 2026 | $2,100 | $16,800 – $25,200 (assuming price reduction) |
| 2027 | $2,050 | $16,400 – $24,750 (further reduction) |
| 2028 | $2,000 | $16,000 – $24,000 |
(Note: Actual prices may vary based on distribution channels, discounts, and negotiated agreements.)
Market Opportunities and Challenges
-
Opportunities:
- Expansion into emerging markets with lower per-capita healthcare expenditure.
- Development of long-acting formulations to increase dosing intervals, potentially commanding premium pricing.
- Strategic partnerships with payers focusing on value-based care to sustain profitability.
-
Challenges:
- Biosimilar competition lowering barriers for substitution.
- Pricing pressures from healthcare policymakers aiming to reduce drug costs.
- The advent of novel therapies demonstrating superior efficacy or convenience.
Regulatory and Policy Influences
Regulatory agencies continue to prioritize biosimilar approval pathways, which could influence biologic drug pricing by introducing competition. Reimbursement reforms aiming to contain healthcare costs, especially in the ophthalmologic sector, could prompt price negotiations and discounts.
Key Takeaways
- Robust Market Position: EYLEA maintains a dominant share in the retinal disorder therapeutics segment, driven by high prevalence and treatment adherence.
- Stable but Slightly Decreasing Prices: List prices are expected to decrease modestly over the coming years due to biosimilar threats and policy pressures, with an estimated 10-15% reduction by 2028.
- Demand Sustainability: The aging population and increasing diabetic incidence will sustain high demand, underpinning revenue continuity.
- Innovation as a Differentiator: Long-acting formulations and combination therapies could redefine pricing strategies and market share dynamics.
- Global Expansion Potential: Emerging markets offer growth opportunities but may influence pricing strategies due to cost sensitivity.
FAQs
1. What is the typical daily dosing frequency of NDC 68180-0739 (EYLEA)?
EYLEA is typically administered via intravitreal injection every 4 to 8 weeks, depending on the indication and disease activity, influencing overall treatment costs.
2. How does biosimilar competition impact the pricing of EYLEA?
While biosimilar development faces regulatory and manufacturing challenges, their eventual entry could lead to significant price reductions, similar to trends seen with other biologics.
3. Are there any regulatory innovations affecting the pricing of NDC 68180-0739?
Regulatory pathways facilitating biosimilar approvals and value-based reimbursement models are expected to influence pricing, encouraging manufacturers to optimize pricing strategies aligned with healthcare cost containment.
4. What are the key factors driving demand growth for anti-VEGF therapies?
The primary drivers include increasing prevalence of AMD and diabetic retinopathy, aging populations, and improvements in diagnostic and treatment technologies.
5. How can manufacturers maintain profitability amid pricing pressures?
Strategies include developing extended-release formulations, optimizing manufacturing efficiency, engaging in value-based pricing negotiations, and expanding into emerging markets.
References
[1] IQVIA. (2022). Pharmaceutical Market Overview.
[2] FDA. (2019). Approval of EYLEA (Aflibercept) for Ocular Conditions.
[3] EvaluatePharma. (2023). Global Ophthalmology Market Data.
[4] Centers for Disease Control and Prevention. (2021). Diabetes and Age-Related Macular Degeneration Epidemiology.
[5] Healthcare Policy Reports. (2022). Impact of Biosimilars on Biologic Pricing.
Disclaimer: This market analysis is based on current publicly available data and trends as of 2023. Actual market conditions may vary based on unforeseen regulatory, technological, or economic developments.
More… ↓
